Skip to main content
. Author manuscript; available in PMC: 2014 Oct 28.
Published in final edited form as: Adv Alzheimer Dis. 2014 Jun;3(2):78–93. doi: 10.4236/aad.2014.32009

Figure 2.

Figure 2

Western blot analysis showing elevation of the levels of β-secretase-1 (BACE1) and GFAP in the LPS-injected relative to PBS-treated (control) brains (n = 4/group), as assayed using hippocampal lysates ipsilateral to the injection. BACE1 levels in the LPS-treated group are about 2 times of that in the control ((A), (B)), while GFAP levels in the LPS group approach to 1.5 times of the control ((A), (C)), with the changes being significant for both proteins (paired two-tail t-tests).